← Research LibraryThe BriefFY2026 10-K · headline figures audited against SEC data
Revenue increased 4.2% to $582.0M, while Net income decreased 2.7% to $106.0M.
The read at a glance✓ Audited against SEC data
- Scale — FY2026 revenue $582.0MOK
- Profitability — Net income $106.0MOK
- Cash generation — Free cash flow $122.3MOK
- Accounting — Formula-grey distress score · no manipulation flag · earnings quality safeNote
- Insiders — 0 buys; 11 sells in 365 daysNote
- Capital — dividends paid were $60.4M; share repurchases were $97.1MNote
Business
EXPONENT INC: B usiness GENERAL Exponent, Inc., together with its subsidiaries, ("Exponent", the "Company", "we", "us" and "our") is a science and engineering consulting firm that provides solutions to complex problems.
Where the revenue comes from
Fiscal 2025, as EXPONENT INC reports it. History and quarterly detail are in the app.
- Engineering And Other Scientific$493.9M
- Environmental And Health$88.1M
Leadership changes
From EXPONENT INC's own filings, the day they're filed.
- John D. Pye · President · appointmenteff. 2026-05-01
- Eric Guyer · President · departureeff. 2024-11-08
- Brian Kundert · Chief Human Resources Officer · appointmenteff. 2024-03-16
Latest filings
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-06-10
- 10-Q · Quarterly report2026-05-08
- 8-K · Company announcement2026-04-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about EXPONENT INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.